Search Results

Founders refine their pitch, rewrite slides, and rehearse explanations. Instead of persuading, founders evaluate alignment. When positioning is unclear, founders default to explanation. Instead of reacting to questions, founders guide the conversation. Founders can quickly assess interest.

In practice, founders overestimate how much time they have, usually by several months. That’s why it’s so dangerous. 👉 The founder shift is this: from scientific immersion → strategic connection Attila runs focused strategy consultations for biotech founders who are ready to lead with clarity, not

For biotech founders, this is more than a presentation problem. It’s a strategic vulnerability. in early-stage biotech pitches, even from smart, well-prepared teams: 1️⃣ Starting with the science Founders follow a clear, strategic logic, not just a narrative arc. 👉 Here’s a four-part structure that helps founders Fast. 👉 Biotech founders don’t lose opportunities because their ideas are weak. Attila runs focused strategy consultations for biotech founders  who are ready to lead with clarity,

Immunotherapy Drug HTL0039732 Exscientia Business Update for Second Quarter and First Half of 2023 Novo Nordisk to acquire Inversago Pharma to develop new therapies for people living with obesity, diabetes

July 2022 "I’m happy to share that I’m starting a new position as Scientific co-founder LASEREDD Therapeutics

Health (RHU) SPRINT consortium grant to progress its proprietary CCR8 antibody candidate to the clinic Novo Radioligand Therapy Production Plant Novartis’ Lutathera reduces disease progression risk in GEP-NET trial Novo Nordisk hits $500 billion in market value as it flags soaring demand for Wegovy, Ozempic Dr.

University’s first female Professor of Chemistry, former president of the Royal Society of Chemistry and Founder highly prestigious international award – exemplified by the fact that other winners this year are the co-founders

Breakthroughs this week:  5-MeO-DMT: the "God Molecule"; Novo Nordisk looks to next generation of obesity

Breakthroughs this week: Novo Nordisk cuts Ozempic® cost; Nxera launches obesity pipeline; Superluminal–Lilly

Submit your logo design by Nov 1st on the Logo Contest page. Company in Immuno-Oncology, Domain Therapeutics, Presents Groundbreaking Advancements at ESMO 2023 Novo Nordisk to Buy Hypertension Treatment from KBP Biosciences Exscientia to Present New Preclinical Data

Most founders are prepared for this on a technical level. Founders feel the pressure to hold everything together. Founders who recognize this early stop asking whether a candidate is impressive. How Founders Can Hire for Survival Without Overengineering It 👉 Once founders recognize that survival For founders, this is not about fixing past hires.

and Provides Business Update Crinetics Pharmaceuticals: Paltusotine Phase 3 Data Presented At ENDO Novo Nordisk to Acquire Inversago Pharma GPCR Events, Meetings, and Webinars NEW Antiverse: Reimagining Therapeutic

Michel Bouvier, J Silvio Gutkind, and team found that Gαs is essential for GRK selectivity and gene regulation Channel Drug Developer Maxion Therapeutics Appoints Eva-Lotta Allan as Chair of its Board of Directors Novo Nordisk and Evotec collaborate to launch LAB eN², a translational drug discovery accelerator, to address

Indeed, incretin-based drugs like Novo Nordisk's Wegovy and Eli Lilly's Zepbound are advancing diabetes

enable the identification of selective antagonists Industry News Inside the FDA's Form 483 findings at Novo Nordisk's North Carolina semaglutide plant Excellerate Bioscience Announces Site Relocation AI can help

Raised To Discover And Advance Novel Oral Small Molecule Medicines Targeting G Protein-Coupled Receptors Novo Nordisk A/S: Semaglutide 2.4 mg reduces the risk of major adverse cardiovascular events by 20% in adults

Research Collaboration with Amgen to Discover Small Molecule Therapeutics using Artificial Intelligence Novo Nordisk Invests 42 Billion Danish Kroner in New Manufacturing Facilities Addex ADX71149 Epilepsy Phase

December 2021 OMass Therapeutics's founder, Carol Robinson, has been awarded the prestigious Louis-Jeantet Prize for Medicine 2022 by the Louis-Jeantet Foundation and the 2022 Benjamin Franklin Medal in Chemistry from The Franklin Institute "Huge congratulations to our founder, Carol Robinson, who has been awarded the prestigious Louis-Jeantet Prize for Medicine 2022 by the Louis-Jeantet Foundation and the 2022 Benjamin

May 2022 "We are thrilled to announce that our co-founder Margaux Duchamp has been selected as a 30 under

April 2022 John Streicher talks about his work on terpenes found in cannabis as these may be a novel

Breakthroughs this week: Decoding ADGRE5 signaling; Eli Lilly’s obesity pill vs Novo’s Wegovy; Certa GPCRs in the spotlight; receptor motion tracking tools; obesity treatment race between Eli Lilly and Novo

This week’s feature goes straight to the foundation: how system-level GPCR thinking  protects discovery Week in Premium: Sneak Peek Industry insights:  Lilly cuts Zepbound prices; Lilly hits $1T valuation; Novo

We’ve shaped everything we do around three interconnected ecosystems: Free , Premium , and Foundry. Strengthening the Foundation You already know our Free Ecosystem  — the podcast, blogs, and Flash News GPCR Foundry  — our R&D and biotech hub designed to bridge GPCR science with execution. The Dr. GPCR Foundry: Science Meets Execution The Foundry is where we bring together biotech innovators, Venture With appreciation and excitement, Yamina Berchiche Founder & CEO, Dr. GPCR About Dr. GPCR Dr.

Yamina Berchiche , Founder and CEO of Dr. GPCR. Reproducible data are foundational to progress in GPCR biology, target validation, and translational reinforces the importance of transparency and community engagement in strengthening the experimental foundations antibody specificity and the reproducibility of GPCR data, contributing to a more robust and reliable foundation About GeneTex GeneTex is a multinational antibody manufacturer founded in 1997, with research and manufacturing

Biologics announce manufacturing agreement  to advance novel anti-CCR8 antibody  for cancer immunotherapy Novo

Your scientific thinking built the foundation, but leadership is what scales it. Let’s unpack the three core “rules” most scientific founders unconsciously carry into their companies In startups, waiting too long for certainty can destroy your momentum . 👉 Biotech founders often delay Founders who keep operating like researchers often create internal confusion. The transition between the two isn’t automatic, even for the most capable founders.

Therapeutics with Generative AI Nxera Pharma receives approval of insomnia drug in Japan Lilly and Novo and UK and Announces the Nomination of Clinical Candidate Against MC2 Call for GPCR Papers Deadline: Nov

Industry insights:  Fresh selectivity datasets on openMe; Novo’s obesity dominance faces new challengers

Welcome to Terry’s Corner , where foundational pharmacology is demystified by someone who’s spent over just look at the data—learn how to read the story it’s telling. 👉 Start your journey with Terry’s foundational

In this foundational lesson, Terry Kenakin dives deep into a widely used, often misunderstood tool in interpretive tools to ask smarter questions, avoid missteps, and use calcium assays with strategic clarity. 📍 Foundational